Aaron is a research consultant for Advisory Board, currently leading a team researching the cross-industry impact of issues related to caring for an aging population.

Before joining Advisory Board's cross-industry team, Aaron worked on dynamics in the payer landscape for the health plan research team. His expertise includes pharmaceutical spend, with a special focus on the financial impact of emerging gene and cell therapies.

Aaron was previously with the NEWDIGS consortium at MIT, where he worked on developing innovative, private-side financing solutions for gene and cell therapies. He holds a PhD from the University of Chicago in modern European history.